Per gentile concessione del Dr. P. Zucali
|
|
- Evelyn Logan
- 8 years ago
- Views:
Transcription
1 La seconda linea di trattamento: scenario attuale e prospettive future Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano
2 mrcc: second line SECOND-LINE SYSTEMIC THERAPY Prior CYTOKINES Prior VEGF-TT Prior mtor-tttt 4% 89% 7% Market shares for 1 st -line systemic treatment in mrcc (% of treated patients) Source: Kantar Health online survey on 75 Oncologists treating mrcc November 2010 (excluding patients on clinical trials)
3 mrcc: second line SECOND-LINE SYSTEMIC THERAPY Prior CYTOKINES Prior Prior VEGF-TT Prior mtor-tttt CYTOKINES 4% 89% 7% Market shares for 1 st -line systemic treatment in mrcc (% of treated patients) Source: Kantar Health online survey on 75 Oncologists treating mrcc November 2010 (excluding patients on clinical trials)
4 TKI Inhibitors after cytokines failure Agent Phase of study N ORR (%) mpfs (months) mos (months) SUNITINIB II II n.r SORAFENIB vs placebo 1 III vs 2 P< vs 2.8 P< vs 15.2 P=0.146 PAZOPANIB vs placebo 2 III vs vs 4.2 P< vs 20.5 P=0.224 AXITINIB vs Sorafenib 3 III vs 9 P= vs 6.5 P< Escudier B, et al. N Engl J Med 2007; 364: Sternberg C, et al. JCO Rini B, et al. Lancet 2011
5 SORAFENIB (TARGET Trial) OS in the cytokine-pretreated population Escudier et al. JCO 2009
6 PAZOPANIB PFS in the cytokine-pretreated subpopulation 1.0 Median PFS (months) Proportion progression-free Placebo 4.2 Pazopanib 7.4 Hazard ratio (95% CI) 0.54 (0.35, 0.84) p value (1-sided) < % reduction in risk of progression or death with pazopanib treatment compared with placebo 0.0 Number at risk, n Pazopanib Placebo Time (month) Pazopanib Placebo Sternberg et al. J Clin Oncol 2010
7 AXITINIB PFS in the cytokine-pretreated subpopulation Rini et al. Lancet 2011
8 mrcc: second line Prior CYTOKINES
9 mrcc: second line Prior CYTOKINES SORAFENIB PAZOPANIB AXITINIB* LEVEL OF EVIDENCE 1 GRADE A RECOMMENDATION
10 mrcc: second line Prior CYTOKINES SORAFENIB PAZOPANIB AXITINIB* SUNITINIB LEVEL OF EVIDENCE 1 GRADE A RECOMMENDATION LEVEL OF EVIDENCE 2 GRADE B RECOMMENDATION *Not yet clinical applicable
11 mrcc: second line SECOND-LINE SYSTEMIC THERAPY Prior CYTOKINES Prior VEGF-targeted THERAPIES Prior mtor-targeted THERAPIES
12 mrcc: second line SECOND-LINE SYSTEMIC THERAPY Prior VEGF-targeted mtor-targeted THERAPIES THERAPIES Prior CYTOKINES Prior mtor-targeted THERAPIES
13 mrcc: second line Prior mtor-targeted THERAPIES
14 mrcc: second line Prior mtor-targeted THERAPIES CLINICAL TRIALS
15 mrcc: second line SECOND-LINE SYSTEMIC THERAPY Prior CYTOKINES Prior VEGF-targeted THERAPIES Prior mtor-targeted THERAPIES
16 mrcc: second line SECOND-LINE SYSTEMIC THERAPY Prior CYTOKINES Prior VEGF-targeted VEGF-targeted THERAPIES THERAPIES Prior mtor-targeted THERAPIES
17 mrcc: second line 1st Line TKIs (Sunitinib-Sorafenib-Pazopanib) 1st Line Bevacizumab+IFNα
18 mrcc: second line 1st Line Bevacizumab+IFNα TKI mtor
19 mrcc: second line 1st Line Bevacizumab+IFNα TKI mtor
20 Bevacizumab Sunitinib Phase II trial PRIMARY END-POINT: ORR 61 SECONDARY END-POINTS: PFS, Response duration, OS, Safety mpfs PR 23% SD 59% Median response duration 44.1 wks OS 47.1 wks Safety (Grade 3 AEs): fatigue 34%; hypertension 18%; HFSR 10% SUNITINIB MAY ACT AT SIGNALLING PATHWAYS INVOLVED IN BEVA-RESISTANCE Rini et al. J Clin Oncol 2008
21 Bevacizumab Axitinib vs Sorafenib Rini BI, et al. Lancet 2011;378: *One-sided log-rank test stratified by ECOG PS
22
23 mrcc: second line after bevacizumab Total patients with 1 treatment VEGF inhibitors IFN + Bevacizumab (AVOREN) (n=327) IFN + placebo (AVOREN) (n=322) 180 (55) 202 (63) Sunitinib 83 (25) 92 (29) 43 45% % Sorafenib 60 (18) 50 (16) Bevacizumab 10 (3) 12 (4) Other 7 (2) 6 (2) mtor inhibitors 14 (4) 6 (2) Cytokines 32 (10) 52 (16) Chemotherapy 28 (9) 47 (15)
24 Final results of AVOREN trial Escudier B, et al. Cancer 2010 OS OS Patients with mrcc (n=649) Stratification by: Country MSKCC risk group Bracarda S, et al. BJUI :1 Avastin + IFN-a2a (n=327) IFN-a2a + placebo (n=322) 23.3 m 21.3 m + TKIs 35% (n=113) + TKIs 37% (n=120) 38.6 m 33.6 m
25 mrcc: second line 1st Line Bevacizumab+IFNα TKI mtor
26 RECORD1: PFS for pts treated with everolimus after bevacizumab + IFN Central Radiology Review Investigator Assessment PFS, progression-free survival; CI, confidence internal. Hutson T. et al. ESMO 2009; abstr P-7136
27 mrcc: second line 1st Line TKIs (Sunitinib-Sorafenib-Pazopanib) 1st Line Bevacizumab+IFNα
28 mrcc: second line 1st Line TKIs (Sunitinib-Sorafenib-Pazopanib) TKI mtor
29 AFINITOR (RECORD-1 Trial) Study Design N = 416 Stratification Prior VEGFr-TKI: 1 or 2 MSKCC risk group: favorable, intermediate, or poor RANDOMISATION (2:1) Everolimus 10mg/day + BSC (n = 277) Upon Disease Progression Placebo + BSC (n = 139) Study Unblinded Safety Interim Analysis 2nd Interim Analysis Data Cut- Off: 15-Oct-07 End of Double- Blind Analysis Data Cut-Off: 28-Feb-08 Survival Follow-Up: 15-Nov patients randomized between December 2006 and November 2007 Analysis cut-off: Feb-28-08, based on 266 PFS events 2nd interim analysis based on cut-off:15-oct-07, efficacy boundary crossed with 410 patients/191 PFS events (Motzer et al. Lancet. 2008;372: ), complete study unblinded on 28-Feb-08
30 PFS by Treatment Central Radiology Review Probability, % Hazard ratio = % CI [0.25, 0.43] Median PFS Everolimus: 4.90 mo Placebo: 1.87 mo Log rank P value = <0.001 Everolimus (n = 277) Placebo (n = 139) > 25 % 0 Patients at risk Everolimus Placebo Months
31 RECORD-1 Subgroup Analysis of PFS (Central Radiology Review) HR P value n Central review 0.33 < Investigator review MSKCC risk Favorable Intermediate Poor Previous treatment Sorafenib only Sunitinib only Both <.001 <.001 < <.001 <.001 < Age < 65 years 0.34 < years 0.33 < Sex Sex Male 0.32 < Female 0.39 < Region USA and Canada 0.29 < Europe 0.38 < Japan and Australia 0.18 < In favor of everolimus In favor of placebo Analysis on Feb 2008 data cutoff. Motzer RJ, et al, for the RECORD-1 Study Group. Cancer. 2010;116(18):
32 Everolimus was as effective after 2 TKIs as it was after 1 TKI 1. Motzer RJ, et al. Cancer 2010;116(18): Hutson TE, et al. Eur J Cancer Suppl. 2009;7(2):Abstract 7136.
33 Selected Adverse Events irrespective of causality Everolimus (n=274) Placebo (n=137) Event, % All Grades Grade 3/4 All Grades Grade 3/4 Stomatitis 44 4/<1 8 0/0 Infections (total) 37 7/3 18 1/0 Asthenia 33 3/<1 23 4/0 Fatigue 31 5/0 27 3/<1 Diarrhea 30 1/0 7 0/0 Rash 29 1/0 16 0/0 Nausea 26 1/0 19 0/0 Mucosal inflammation 19 1/0 1 0/0 Edema peripheral 25 <1/0 8 <1/0 Dyspnea 24 6/1 15 3/0 Pneumonitis 14 4/0 0 0/0 Updated information from Motzer RJ, et al, for the RECORD-1 Study Group. Cancer. 2010;116(18):
34 Laboratory Abnormalities irrespective of causality Everolimus Placebo (n = 274) (n = 137) Event, % All Grades Grade 3/4 All Grades Grade 3/4 Hematology Anemia 92 12/1 79 5/<1 Lymphopenia 51 16/2 28 5/0 Thrombocytopenia 23 1/0 2 0/<1 Chemistry Hypercholesterolemia 77 4/0 35 0/0 Hypertriglyceridemia 73 <1/0 34 0/0 Hyperglycemia 57 15/<1 25 1/0 Elevated creatinine 50 1/0 34 0/0 Updated information from Motzer RJ, et al, for the RECORD-1 Study Group. Cancer. 2010;116(18):
35 Medical optimization of TORisel (MoTOR): A multicenter, phase II evaluation of Torisel as II-line treatment for metastatic RCC patients progressing after cytokine therapy, tyrosine kinase, or angiogenesis inhibitors Primary Endpoint: PFS rate at 6 mos Entire series: mpfs 4.0 mos (95% CI: ) Sunitinib pretreated: mpfs 4.6 mos (95% CI: ) 18/57 pts free from progression at 6 mos in the sunitinibpretreated group. PRIMARY ENDPOINT WAS MET GIR-2 study
36 mrcc: second line 1st Line TKIs (Sunitinib-Sorafenib-Pazopanib) TKI mtor
37 TKI-TKI Sequence: many retrospective and few prospective phase II trials Hutson et al. Clin Rev Oncol 2011
38 TKI-TKI Sequence: no cross-resistanceresistance SUNITINB SORAFENINB mpfs or TTP: mos SORAFENINB SUNITINB mpfs or TTP: mos Hutson et al. Clin Rev Oncol 2011
39 AXIS TRIAL
40 AXIS Study Design Patients with clear cell metastatic RCC and RECIST PD after 1 prior systemic firstline regimen: Sunitinib, Bevacizumab + IFN-α, Temsirolimus, or Cytokine(s) 1:1 Axitinib 5 mg BID* (n=361) PRIMARY END-POINT: PFS Sorafenib 400 mg BID (n=362) Randomization stratified by ECOG PS and type of prior treatment * Starting dose 5 mg BID with option for dose titration to 10 mg BID 4 0
41 Progression-free Survival: all population (IRC Assessment) Progression-Free Survival (probability) Subjects at risk, n Axitinib Sorafenib IRC = Independent Review Committee Time (months) mpfs, mo 95% CI Axitinib Sorafenib , , 5.6 P< (log-rank) Stratified HR (95% CI: 0.544, 0.812) Rini BI, et al. Lancet 2011
42 Rini BI, et al. Lancet 2011;378: *One-sided log-rank test stratified by ECOG PS
43 Rini BI, et al. Lancet 2011;378: *One-sided log-rank test stratified by ECOG PS
44 AXITINIB PFS in the TKI-pretreated subpopulation Rini et al. Lancet 2011
45
46 AXIS trial: Final Overall Survival
47 AXIS trial: Final Overall Survival
48 Per Per gentile concessione del del Dr. Dr. P. P. Zucali
49 Per Per gentile concessione del del Dr. Dr. P. P. Zucali
50 Axitinib Dose Titration in AXIS Trial Starting dose 5 mg BID n=359 (100%) Dose reduction <5 mg BID n=88 (25%) No dose change 5 mg BID n=139 (39%) Mean duration: 161 days Dose escalation >5 mg BID n=132 (37%) Highest titration to 7 mg BID n=60 (17%) Mean duration (7 mg BID): 92 days Highest titration to 10 mg BID n=71 (20%) Mean duration (10 mg BID): 127 days Patients whose dose increased and then reduced n=71 (20%) No substantial difference in ability to dose titrate >5 mg BID based on prior treatment, ethnicity, gender, or region 50
51 Progression-free Survival Survival Distribution Function Axitinib 5 mg BID Axitinib >5 mg BID Sorafenib PFS (months) 51
52 Summary of Treatment-emergent, All-Causality Adverse Events 5 mg BID a (n=227) Axitinib Dose, n (%) >5 mg BID b (n=132) Any AEs 216 (95.2) 126 (95.5) Diarrhea 120 (52.9) 77 (58.3) Decreased appetite 66 (29.1) 57 (43.2) Nausea 60 (26.4) 56 (42.4) Fatigue 89 (39.2) 51 (38.6) Hypertension 97 (42.7) 48 (36.4) Hypothyroidism 22 (16.7) 47 (20.7) Dysphonia 71 (31.3) 40 (30.3) Asthenia 36 (15.9) 38 (28.8) Palmar-plantar erythrodysesthesia syndrome 63 (27.8) 35 (26.5) Proteinuria 28 (12.3) 11 (8.3) a No total daily dose of axitinib >5 mg BID, b 1 total daily dose of axitinib >5 mg BID. 52
53 Summary of PFS by Duration of Prior Sunitinib PFS, months (95% CI), [n] <3 mo vs 3 mo <6 mo vs 6 mo <9 mo vs 9 mo Axitinib 4.5 (2.7, NR) [22] 4.8 (4.5, 6.5) [170] 4.6 (2.8, 8.3) [48] 4.8 (3.6, 6.5) [144] 4.5 (2.8, 6.4) [90] 6.3 (4.6, 6.7) [102] Sorafenib 2.8 (1.4, 15.7) [21] 3.7 (2.8, 4.7) [173] 2.8 (1.6, 3.7) [62] 4.6 (2.9, 4.9) [132] 2.9 (2.8, 4.6) [87] 4.6 (2.9, 4.9) [107]
54 PFS by Prior Response to Sunitinib: Axitinib vs Sorafenib Arms Axitinib Sorafenib Non-responders Responders n mpfs mo % CI Non-responders Responders n mpfs mo % CI Probability of PFS Time (months) Time (months) 0
55 mrcc: second line Prior VEGF-targeted THERAPIES TKI mtor AXITINIB LEVEL OF EVIDENCE 1 GRADE A RECOMMENDATION EVEROLIMUS LEVEL OF EVIDENCE 1 GRADE A RECOMMENDATION SU-SO SO or SO-SUSU LEVEL OF EVIDENCE 2 GRADE B RECOMMENDATION
56 BEST SEQUENCE: TKI-TKI or TKI-mTOR? Suggestions for clinical practice
57 The Optimal Sequence TKI VEGF Inhibitor 1 Phase III data mtor Inhibitor Limited data? TKI VEGF Inhibitor 1 TKI VEGF Inhibitor 2 mtor Inhibitor Phase III data Phase III data
58 Clinical practice No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
59 Clinical practice No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
60 Clinical practice: primary recfractory pts 1. Vickers MM, et al. Urology 2010;76:430-4; 2. Heng DY, et al. Abs. ASCO GU 2011; Albiges L, et al. (manuscript submitted)0
61 Clinical practice: primary recfractory pts Phase III study PD as best response Bevacizumab 20% Pazopanib 18% Sunitinib 12% Sorafenib 20% 1. Vickers MM, et al. Urology 2010;76:430-4; 2. Heng DY, et al. Abs. ASCO GU 2011; Albiges L, et al. (manuscript submitted)0
62 Clinical practice: primary recfractory pts Large retrospective series (the mrcc International Data-Base Consortium, as well as the French-Italo-British cooperative study) 1-3 : 2 PFS TKI 2 PFS mtor OS from 2 line Heng 2,8 mo 2,0 mo 7,4 mo Albiges 6,6 mo 5,0 mo 5,9 mo in TKI-primary refractory patients (i.e., a mtor inhibitor) 1. Vickers MM, et al. Urology 2010;76:430-4; 2. Heng DY, et al. Abs. ASCO GU 2011; Albiges L, et al. (manuscript submitted)0
63 Relative Potencies of TKIs in RCC 1. Eskens FALM, et al. In: Proceedings of the 99th Annual Meeting of the AACR. San Diego, CA: AACR; Abstract LB Nakamura K, et al. Cancer Res. 2006;66(18): Chow LQM, Eckhardt SG. J Clin Oncol. 2007;25(7):
64 REACT trial RAD001 Expanded Access Clinical Trial in RCC Pts with mrcc intollerant of, or progressed while on, VEGFR-TKI therapy EVEROLIMUS treatment duration by prior therapy All PD on prior VEGFR-TKI Intolerant Treated with Treated with to prior only 1 prior only prior VEGFR-TKI VEGFR-TKI sunitinib n Treatment duration (wks) Larkin JMG, ASCO GU 2012
65 Clinical practice No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
66 Clinical practice No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
67 Clinical practice No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
68 AXIS versus RECORD-1 1. Motzer RJ, et al. Lancet 2008;372:449-56; 2. Rini BI, et al. Lancet 2011;378: Bex A., Lancet 2011
69 RECORD1: a real 2nd line trial? (more than 75% of pts in RECORD-1 received everolimus as 3rd+ Line) Patients received a median of 2 prior antineoplastic medications Per gentile Motzer concessione RJ, Cancer del Dr P. Zucali
70 Second line: mtor vs TKI 2100 pts VEGF-targeted therapy 1st LINE 645 pts VEGF-targeted therapy 818/2100 pts -541 pts VEGF-TT -277 pts mtor-tttt 2nd LINE 216/645 pts -192 pts VEGF-TT -24 pts mtor-tttt Heng et al. ASCO GU 2012 Vickers et al. Urology 2010
71 Second line: mtor vs TKI Vickers et al. Urology 2010 VEGF-TT VEGF-TT vs VEGF-TT mtor-tt HR for death: 0.833* (p 0.10) *adjusted for: Heng poor criteria, non-clear cell histology Heng et al. ASCO GU 2012
72 Second line: mtor vs TKI in long responders From a large retrospective European cooperative series1, we now know that: in those patients who have had a clear-cut and long-lasting benefit from a first-line TKI, (either another TKI, or a mtor inhibitor) 1 This is probably due by the fact that in RCC is so heavily dependant on angiogenesis, inhibiting mtor ultimately results in a continuous, even though indirect, inhibition of angiogenesis. 1. Eladi R, et al. (manuscript in preparation)
73 No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
74 No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
75 DIFFERENT TOXICITY PROFILES TKI mtor inhibitor TKI
76 PROFILI DI TOSSICITA
77
78 No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
79 No response Intolerance Short term benefit Long term benefit Porta C, et al. EJMCO 2010 Eisen T, modified
80 In the absence of PREDICTIVE BIOMARKERS..
81 Tolerability Profiles Can Help to Guide Selection of Treatment: Patient-related Factors and Comorbidities Patient with reduced EF Patient with nutrition disorders Patients with impaired mobility Consider the patient's profession Consider comedications (drug interactions) Chronic obstructive pulmonary disease Thromboembolic disease Diabetes Mellitus
82 Clinical trials!
83 Second-line therapy: ongoing trials Trial Prior treatment Design End-point Status SWITCH Phase III NCT Sorafenib Sunitinib Vs Sunitinib Sorafenib PFS Recruiting (n=346) RECORD-3 Phase III NCT Everolimus Sunitinib Vs Sunitinib Everolimus PFS Recruiting (n=390) Pazopanib Bevacizumab START Phase II NCT Pazopanib Everolimus Everolimus Pazopanib Everolimus Bevacizumab Bevacizumab Everolimus TTF Recruiting (n=240) Bevacizumab Pazopanib Phase III NCT TKIs Bevacizumab Vs Beva + Eve OS Recruiting (n=700) Phase III NCT Sunitinib Temsirolimus Vs Sorafenib PFS Recruiting (n=480)
84 VEGFR and mtor pathways
85 Alternate Angiogenic Signalling Pathways Afford Novel Targets in RCC
86 FGF mediates escape from anti-vegf therapy FGF2 is expressed by numerous tumor types and exerts its proangiogenic activity by interacting with TK receptors, heparan-sulfate proteoglycans, and integrins expressed on the endothelial cell surface Early phase: VEGFR2 blockade transiently stops tumor growth and decreases vascularity Casanovas O, et al. Cancer Cell 2005;8: Late phase: Reactivation of angiogenesis after anti-vegfr VEGFR2 therapy through FGF activation leads to tumorprogression
87 Horizontal Inhibition May Delay Development of Resistance
88 DOVITINIB Demonstrates Activity in Heavily Pretreated mrcc Patients Angevin E et al. ASCO Abs 3057.
89 Phase III Dovitinib in mrcc (third line)
90 AMG-386, an Angiopoeitin Antagonist With Antitumour Efficacy
91 Phase 2: AMG Sorafenib Increases Response but not PFS Over Sorafenib in RCC
92 PI3K/Akt/mTOR Signalling Figure adapted from Rini BI, Atkins MB. Lancet Oncol. 2009;10:
93 PERIFOSINE, an Oral Alkylphospholipid, Shows Clinical Benefit in Refractory mrcc
94 HGF/cMET Signalling ARQ-197 Foretinib ORR 13.5%; PFS 9.3 mos; 1yr OS 70% papillary RCC. Pts METmut+ PR 50%; DCR 100%. Cabozantinib (XL187) PR 24%; DCR 68%; tumor shrinkage 86% in refractory RCC. Choueiri et al. ASCO GU 2012
95 Immunotherapy?
96 Immunotherapy: ongoing trials Target Drug Class Development phase Blockade of T-cell regulation PD-1 antibody MDX-1106 Fully human mab Phase II CTLA-4 antibody Ipilimumab Fully human IgG1 mab Phase III (melanoma) Inhibition of tumor-induced T-cell function TGF-beta GC1008 Fully human mab Phase I TGF-beta AP12009 Fully human mab Phase I T-cell activation CD137 BMS Monoclonal Ab Phase I Cytokines Interleukin-21 Recombinant molecule Phase II (melanoma) Dendritic cell activation Toll-like receptor HYB-2055 TLR-9 agonist Phase II Dendritic celltumor fusions AGS-003 Dendritic cell-based immunotherapy Phase III
97 Conclusions After a first-line Cytokine therapy, TKIs (Level 1: pazopanib, axitinib, sorafenib; level 2: sunitinib) are the first options. After a first-line mtor-targeted therapy, patients should be included in clinical trials. After a first-line VEGF-targeted therapy, in the absence of specific comparative trials, another TKI or a mtor-inhibitor are both reasonable treatment options. No specific sequences emerged, to date, as the ideal ones. A continuous inhibition of angiogenesis appears to be key in this peculiar cancer. However, new targets should be explored (i.e. cmet, PI3K, FGFr, Angiopoietin/Tie2).
98 Grazie per l attenzione
Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationPROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationPrecision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma
Perspective Precision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma Parth K. Modi 1, Nicholas J. Farber 1, Eric A. Singer 1,2 1 Division of Urology, Rutgers
More informationTumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta S.C. di Oncologia Medica, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia Non-Clear Cell Renal Cell Carcinoma (nccrcc) nccrcc
More informationTargeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms
Targeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms Wolfram Samlowski, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then
More informationSuccesses and Limitations of Targeted Therapies in Renal Cell Carcinoma
g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,
More information54,390 estimated new cases of RCC 13,010 estimated deaths. Incidence is increasing 2.0% per year
Advanced Renal Cell Carcinoma Individualizing Treatment Selection in the Era of Targeted Therapy Renal Cell Carcinoma In the United States in 28: 54,9 estimated new cases of RCC, estimated deaths Median
More informationCome valutare la risposta o la progressione nei pazienti in trattamento con terapie biologiche
Come valutare la risposta o la progressione nei pazienti in trattamento con terapie biologiche Andrea Busolo U.O. di Radiologia Rocco De Vivo U.O. di Oncologia Medica ULSS 6 - Vicenza Activity and efficacy
More informationONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico
ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico Sequenza ottimale del trattamento Maria Teresa Scognamiglio U.O.C. Clinica Oncologica Chieti-Ortona Chieti 12 novembre 213
More informationSorafenib. Bernard ESCUDIER Institut Gustave Roussy Villejuif, France
Sorafenib for renal cell carcinoma Bernard ESCUDIER Institut Gustave Roussy Villejuif, France Renal Cell Carcinoma: Drugs and Targets pvhl = HIFα CCI-779 Bevacizumab VEGF KDR PDGF PDGFR TGFα EGFR Sunitinib,
More informationImmunotherapy for Metastatic Renal Cell Carcinoma
Immunotherapy for Metastatic Renal Cell Carcinoma Timothy M. Kuzel, MD Professor of Medicine and Dermatology Feinberg School of Medicine Northwestern University Chicago, Ilinois ICLIO 1 st Annual National
More informationmrcc: Tratamiento HOY de segunda línea Pablo Maroto Htal Sant Pau
mrcc: Tratamiento HOY de segunda línea Pablo Maroto Htal Sant Pau El CCRm precisa de una estrategia de tratamiento Los agentes anti-diana constituyen el tratamiento estandar del CCRm. Pero.. Cómo combinarlos?
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationBJUI. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment
2009 The Authors; Journal compilation 2009 BJU International Mini-review Article MANAGEMENT ALGORITHMS FOR METASTATIC RCC BELLMUNT et al. BJUI BJU INTERNATIONAL Optimal management of metastatic renal cell
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationCarcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba Europe 121 629 new cases RCC 2012, 75 676 affected men Slide 3
More information2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationCáncer Renal avanzado. Nuevas estrategias para el tratamiento individualizado.
Cáncer Renal avanzado. Nuevas estrategias para el tratamiento individualizado. Daniel Castellano Oncología Médica.Unidad de Tumores GenitoUrinarios Hospital Universitario 12 de Octubre. I + 12 Research
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationTitle: Making Optimal Therapeutic Decisions in Patients with Advanced Renal Cell Carcinoma
Overall Aim and Objectives: Program Synopsis Title: Making Optimal Therapeutic Decisions in Patients with Advanced Renal Cell Carcinoma Clinical Synopsis: New options for targeted treatment of metastatic
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationHow To Understand The Effects Of A Drug On Your Health
Farmacologia degli inibitori TK e mtor Romano Danesi Professore ordinario di Farmacologia UOC Farmacologia Universitaria Azienda Ospedaliero-Universitaria Pisana Dipartimento di Medicina Interna Università
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationTargeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationNOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Philippe RUSZNIEWSKI
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Réunion APRAMEN, Paris, 2 février 2013 Philippe RUSZNIEWSKI Pôle des Maladies de
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Pazopanib (Votrient ) for the treatment of locally advanced and/or metastatic renal cell carcinoma DSD: Horizon Scanning in Oncology Nr. 013 ISSN online 2076-5940 Horizon
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationSequential Treatment Strategies and Combination Therapy Regimens in Metastatic Renal Cell Carcinoma
Sequential Treatment Strategies and Combination Therapy Regimens in Metastatic Renal Cell Carcinoma Sumanta Kumar Pal, MD, and Nicholas J. Vogelzang, MD Dr. Pal is an Assistant Professor of Genitourinary
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationSeconda linea di trattamento
XVIII Congresso Nazionale CIPOMO Roma, Giugno 2013 Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Seconda linea di trattamento Giorgio
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationNieuwe ontwikkelingen op het gebied van de angiogeneseremmers
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Emile Voest, MD, PhD Department of Medical Oncology University Medical Center Utrecht the Netherlands 4e Nascholing Targeted Therapy April
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationFoundational Issues Related to Immunotherapy and Melanoma
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationApproccio multidisciplinare nel carcinoma della vescica. D. Amoroso Dip. di Oncologia Medica Ospedale Versilia Lido di Camaiore (LU)
Approccio multidisciplinare nel carcinoma della vescica D. Amoroso Dip. di Oncologia Medica Ospedale Versilia Lido di Camaiore (LU) Disclosures Advisory Role, Honoraria: ü Roche ü Italfarmaco Outline v
More informationDrug treatments for kidney cancer
James Whale Fund for Kidney Cancer Drug treatments for kidney cancer Before your doctors can discuss treatment options with you they need to know how far your cancer has progressed. Staging is used to
More informationMultiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple
More informationClinical Spotlight in Breast Cancer
2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared
More informationThe role of PARP inhibitors in high grade serous ovarian cancers
The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationImmuno-Oncology 2015: A New Landscape in Lung Cancer
Immuno-Oncology 2015: A New Landscape in Lung Cancer David R. Spigel, M.D. Lung Cancer Program Director Sarah Cannon Research Institute/Tennessee Oncology, PLLC Nashville, TN Off-Label Use Disclosure(s)
More informationTargeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page Sponsor Novartis Generic Drug Name BGT6 Therapeutic Area of Trial Advanced solid malignancies Approved Indication Investigational Study Number CBGT6A0 Title A phase
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationClinical Trials for Patients with
Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,
More informationTreatment Paradigm in NSCLC Treatment
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
More informationCorporate Presentation June 2, 2015
Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these
More informationPrognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma.
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. Iacovelli R 1, Farcomeni A 2, Sternberg CN 3, Carteni G 4, Milella M 5, Santoni M 6, Cerbone L
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationTreating Hepatocellular Carcinoma: Medical Oncology Options
Treating Hepatocellular Carcinoma: Medical Oncology Options W. Thomas Purcell, MD, MBA Gastrointestinal Oncology Phase I / Developmental Therapeutics Group Executive Medical Director University of Colorado
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationMelanoma and Immunotherapy
Melanoma and Immunotherapy Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA The Transformed Landscape
More informationClinical Trials in non-clear cell RCC: ESPN, ASPEN and beyond
Clinical Trials in non-clear cell RCC: ESPN, ASPEN and beyond Toni K. Choueiri, MD Clinical Director and Kidney Cancer Center Director The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute
More informationMedia Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986
News Release Media Contacts: Annick Robinson Investor Contacts: Teri Loxam (438) 837-2550 (908) 740-1986 Merck Announces Initial Results for Pembrolizumab with Novel Immunotherapy Combinations from Three
More informationComparing Immunotherapy with High Dose IL-2 and Ipilimumab
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC mike.wong@med.usc.edu Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
More informationWhat s new in prostate cancer research? Highlights of GU-ASCO 2014
review What s new in prostate cancer research? Highlights of GU-ASCO 2014 Cite as: Can Urol Assoc J 2014;8(3-4Suppl2):S8-12. http://dx.doi.org/10.5489/cuaj.2013 Published online April 14, 2014. Abstract
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationBiomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
More informationGastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/
Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second
More informationThe New Kid on the Block for Advanced Renal Cell Carcinoma
The New Kid on the Block for Advanced Renal Cell Carcinoma Wyeth Pharmaceuticals recently launched Torisel (temsirolimus), a targeted, first-in-class mtor inhibitor. This new treatment for metastatic renal
More informationCML Drugs and their Availability in the UK. Jane Apperley
CML Drugs and their Availability in the UK Jane Apperley Drugs used in the treatment of CML Traditional chemotherapy Busulphan Hydoxycarbamide Interferon-alpha Omacetaxine Tyrosine kinase inhibitors Imatinib
More informationAdditional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points
News Release Media Contacts: Annick Robinson Dominique Quirion Merck NATIONAL Annick.robinson@merck.com dquirion@national.ca 514 428-2890 514 843-2302 Investor Contacts: Justin Holko: (+1 908-423-5088
More informationLatest developments in management. Gianfilippo Bertelli Consultant Medical Oncologist Swansea
Latest developments in management Gianfilippo Bertelli Consultant Medical Oncologist Swansea Optimizing management of ovarian cancer in South Wales Diagnosis and referral pathways: Role of GPs, gynaecologists,
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationEndpoint Selection in Phase II Oncology trials
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationMOLOGEN AG. Dr. Matthias Schroff Chief Executive Officer Dr. Alfredo Zurlo Chief Medical Officer. Roadshow Abu Dhabi, Dubai April 2015
Dr. Matthias Schroff Chief Executive Officer Dr. Alfredo Zurlo Chief Medical Officer Roadshow Abu Dhabi, Dubai April 2015 Disclaimer Certain statements in this presentation contain formulations or terms
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationCritical Pathways Forward in the Treatment of Renal Cell Carcinoma
Critical Pathways Forward in the Treatment of Renal Cell Carcinoma Based on an Expert Summit convened in Washington, DC, July 30-31, 2012 Key Points 1. The approval of seven agents, all targeting angiogenesis,
More information